基于他汀类药物的不同降脂策略对稳定型冠心病患者 C 反应蛋白水平的影响

IF 2.4 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Clinical Cardiology Pub Date : 2024-06-19 DOI:10.1002/clc.24301

Zhimin Xue, Miao Ye, Hangpan Jiang, Duanbin Li, Xulin Hong, Zhezhe Chen, Ya Li, Binquan Zhou, Wenbin Zhang, Miaoyun Wang

{"title":"基于他汀类药物的不同降脂策略对稳定型冠心病患者 C 反应蛋白水平的影响","authors":"Zhimin Xue, Miao Ye, Hangpan Jiang, Duanbin Li, Xulin Hong, Zhezhe Chen, Ya Li, Binquan Zhou, Wenbin Zhang, Miaoyun Wang","doi":"10.1002/clc.24301","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Statins are lipid-lowering drugs with favorable anti-inflammatory effects. This study aimed to explore different statin-based lipid-lowering strategies to reduce high-sensitivity C-reactive protein (hs-CRP).</p>\n </section>\n \n <section>\n \n <h3> Hypothesis</h3>\n \n <p>The hypothesis is that different statin-based lipid-lowering strategies might reduce hs-CRP.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This retrospective study included 3653 patients who underwent percutaneous coronary intervention (PCI). Three statin-based lipid-lowering strategies were investigated, including different types of statins (atorvastatin vs. rosuvastatin), statin combined with ezetimibe therapy (vs. without), and intensive statin therapy (vs. regular). The hs-CRP levels and blood lipid indicators were measured at baseline and after 1-month lipid-lowering therapy. Multivariable linear regression analysis and structural equation mode analysis were conducted to verify the association between different lipid-lowering strategies, Δhs-CRP (%) and ΔLDL-C (%).</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Totally, 3653 patients were enrolled with an average age of 63.81 years. Multivariable linear regression demonstrated that statin combined with ezetimibe therapy was significantly associated with decreased Δhs-CRP (%) (<i>β</i> = −0.253, 95% CI: [−0.501 to −0.005], <i>p</i> = 0.045). The increased ΔLDL-C (%) was an independent predictor of elevated levels of Δhs-CRP (%) (<i>β</i> = 0.487, 95% CI: [0.15−0.824], <i>p</i> = 0.005). Furthermore, structural equation model analysis proved that statin combined with ezetimibe therapy (<i>β</i> = −0.300, <i>p</i> < 0.001) and intensive statin therapy (<i>β</i> = −0.032, <i>p</i> = 0.043) had an indirect negative effect on Δhs-CRP via ΔLDL-C.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Compared with routine statin use, statin combined with ezetimibe therapy and intensive statin therapy could further reduce hs-CRP levels.</p>\n </section>\n </div>","PeriodicalId":10201,"journal":{"name":"Clinical Cardiology","volume":"47 6","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2024-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clc.24301","citationCount":"0","resultStr":"{\"title\":\"The Effect of Different Statin-Based Lipid-Lowering Strategies on C-Reactive Protein Levels in Patients With Stable Coronary Artery Disease\",\"authors\":\"Zhimin Xue, Miao Ye, Hangpan Jiang, Duanbin Li, Xulin Hong, Zhezhe Chen, Ya Li, Binquan Zhou, Wenbin Zhang, Miaoyun Wang\",\"doi\":\"10.1002/clc.24301\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>Statins are lipid-lowering drugs with favorable anti-inflammatory effects. This study aimed to explore different statin-based lipid-lowering strategies to reduce high-sensitivity C-reactive protein (hs-CRP).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Hypothesis</h3>\\n \\n <p>The hypothesis is that different statin-based lipid-lowering strategies might reduce hs-CRP.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>This retrospective study included 3653 patients who underwent percutaneous coronary intervention (PCI). Three statin-based lipid-lowering strategies were investigated, including different types of statins (atorvastatin vs. rosuvastatin), statin combined with ezetimibe therapy (vs. without), and intensive statin therapy (vs. regular). The hs-CRP levels and blood lipid indicators were measured at baseline and after 1-month lipid-lowering therapy. Multivariable linear regression analysis and structural equation mode analysis were conducted to verify the association between different lipid-lowering strategies, Δhs-CRP (%) and ΔLDL-C (%).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>Totally, 3653 patients were enrolled with an average age of 63.81 years. Multivariable linear regression demonstrated that statin combined with ezetimibe therapy was significantly associated with decreased Δhs-CRP (%) (<i>β</i> = −0.253, 95% CI: [−0.501 to −0.005], <i>p</i> = 0.045). The increased ΔLDL-C (%) was an independent predictor of elevated levels of Δhs-CRP (%) (<i>β</i> = 0.487, 95% CI: [0.15−0.824], <i>p</i> = 0.005). Furthermore, structural equation model analysis proved that statin combined with ezetimibe therapy (<i>β</i> = −0.300, <i>p</i> < 0.001) and intensive statin therapy (<i>β</i> = −0.032, <i>p</i> = 0.043) had an indirect negative effect on Δhs-CRP via ΔLDL-C.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>Compared with routine statin use, statin combined with ezetimibe therapy and intensive statin therapy could further reduce hs-CRP levels.</p>\\n </section>\\n </div>\",\"PeriodicalId\":10201,\"journal\":{\"name\":\"Clinical Cardiology\",\"volume\":\"47 6\",\"pages\":\"\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2024-06-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clc.24301\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Cardiology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/clc.24301\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Cardiology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/clc.24301","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

摘要

背景：他汀类药物是具有良好抗炎作用的降脂药物。本研究旨在探讨基于他汀类药物的不同降脂策略，以降低高敏 C 反应蛋白（hs-CRP）：假设：基于他汀类药物的不同降脂策略可降低高敏C反应蛋白：这项回顾性研究纳入了3653名接受经皮冠状动脉介入治疗（PCI）的患者。研究了三种基于他汀类药物的降脂策略，包括不同类型的他汀类药物（阿托伐他汀与罗苏伐他汀）、他汀类药物联合依折麦布治疗（与不联合依折麦布治疗）以及强化他汀类药物治疗（与常规治疗）。hs-CRP水平和血脂指标分别在基线和降脂治疗1个月后测量。通过多变量线性回归分析和结构方程模式分析来验证不同降脂策略、Δhs-CRP（%）和ΔLDL-C（%）之间的关联：共纳入 3653 名患者，平均年龄为 63.81 岁。多变量线性回归结果表明，他汀联合依折麦布治疗与Δhs-CRP（%）的降低显著相关（β = -0.253，95% CI：[-0.501 至 -0.005]，p = 0.045）。ΔLDL-C（%）的升高是Δhs-CRP（%）升高的独立预测因子（β = 0.487，95% CI：[0.15-0.824]，p = 0.005）。此外，结构方程模型分析证明，他汀类药物联合依折麦布治疗（β = -0.300，p 结论：依折麦布与他汀类药物联合治疗的疗效更佳：与常规使用他汀相比，他汀联合依折麦布疗法和强化他汀疗法可进一步降低 hs-CRP 水平。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The Effect of Different Statin-Based Lipid-Lowering Strategies on C-Reactive Protein Levels in Patients With Stable Coronary Artery Disease

Background

Statins are lipid-lowering drugs with favorable anti-inflammatory effects. This study aimed to explore different statin-based lipid-lowering strategies to reduce high-sensitivity C-reactive protein (hs-CRP).

Hypothesis

The hypothesis is that different statin-based lipid-lowering strategies might reduce hs-CRP.

Methods

This retrospective study included 3653 patients who underwent percutaneous coronary intervention (PCI). Three statin-based lipid-lowering strategies were investigated, including different types of statins (atorvastatin vs. rosuvastatin), statin combined with ezetimibe therapy (vs. without), and intensive statin therapy (vs. regular). The hs-CRP levels and blood lipid indicators were measured at baseline and after 1-month lipid-lowering therapy. Multivariable linear regression analysis and structural equation mode analysis were conducted to verify the association between different lipid-lowering strategies, Δhs-CRP (%) and ΔLDL-C (%).

Results

Totally, 3653 patients were enrolled with an average age of 63.81 years. Multivariable linear regression demonstrated that statin combined with ezetimibe therapy was significantly associated with decreased Δhs-CRP (%) (β = −0.253, 95% CI: [−0.501 to −0.005], p = 0.045). The increased ΔLDL-C (%) was an independent predictor of elevated levels of Δhs-CRP (%) (β = 0.487, 95% CI: [0.15−0.824], p = 0.005). Furthermore, structural equation model analysis proved that statin combined with ezetimibe therapy (β = −0.300, p < 0.001) and intensive statin therapy (β = −0.032, p = 0.043) had an indirect negative effect on Δhs-CRP via ΔLDL-C.

Conclusions

Compared with routine statin use, statin combined with ezetimibe therapy and intensive statin therapy could further reduce hs-CRP levels.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical Cardiology 医学-心血管系统

CiteScore

5.10

自引率

3.70%

发文量

189

审稿时长

4-8 weeks

期刊介绍： Clinical Cardiology provides a fully Gold Open Access forum for the publication of original clinical research, as well as brief reviews of diagnostic and therapeutic issues in cardiovascular medicine and cardiovascular surgery. The journal includes Clinical Investigations, Reviews, free standing editorials and commentaries, and bonus online-only content. The journal also publishes supplements, Expert Panel Discussions, sponsored clinical Reviews, Trial Designs, and Quality and Outcomes.